Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Soleno Therapeutics, Inc.
SLNO
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.8B
$53.01
▲ 0.00%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$29.43 - $90.32
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 32.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Focused pipeline targeting rare genetic disorder with limited treatment options
- Once-daily oral formulation improving patient compliance and quality of life
- Specialized expertise in rare disease development and regulatory pathways
- First-mover advantage in DCIR development for PWS indication
Bear Case
1 risk
- Low volatility (beta -2.2).
Growth
Strong growth ahead
Phase III clinical trial progression and potential regulatory approval of DCIR
Value
Undervalued - trading well below Biotech & Therapeutics peers
Momentum
Hot
+57.0% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SLNO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 5, 2026
MAY 7, 2026
Reported EPS of $0.60 vs $0.68 consensus (-11.8% surprise). Revenue of $94.6M vs $93.8M expected (+0.9%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-11.8%
Next: May 5, 2026
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$0
$0
$0
$0
$32.7M
$66.0M
$91.7M
$94.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
33.2%
Wall Street consensus
6 analysts · 17% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
17%
Hold
83%
Sell
0%
Median Price Target
$53.00
▼ -0.0% vs $53.01
Latest: Wells Fargo · $53.00 · Apr 17, 2026
1 analyst covering